Shared insight on the current treatment landscape for myeloproliferative neoplasms (MPNs), including novel therapies for essential thrombocythemia (ET), polycythemia vera (PV), and myelofibrosis (MF).
Adjuvant Chemoradiotherapy Demonstrated Better Outcomes for Patients With Endometrial Cancer
As Rare Disease Day Approaches, I’m Reflecting on My MPN Diagnosis
First Patient Injected With Novel Radiotherapy in Phase 2b Trial for Brain Cancer
FDA Approves Orserdu for Some Patients with Metastatic Breast Cancer